Genprex Key Opinion Leader Event Hosted by Alliance Global Partners

The event, titled, “Advances in Gene Therapy for Oncology: New Opportunities with REQORSA™ (TUSC2),” was moderated by James Molloy, Managing Director, Equity Research at AGP and featured discussions on Genprex’s novel immunogene therapy for lung cancer, with experts Andrew Becker, M.D., Ph.D. and COL (ret) George Peoples, M.D., FACS. This event was recorded on April 27, 2021. Since the recording, Genprex has initiated its Acclaim-1 clinical trial and has made modifications to its Acclaim-2 protocol.